Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NEK7 | Q8TDX7 | 6/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172650 | 0.93 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10171960 | 0.93 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10172016 | 0.91 | GPR119 (0.47) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10171922 | 0.91 | GPR119 (0.49) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10172179 | 0.90 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10172706 | 0.89 | GPR119 (0.48) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10172614 | 0.87 | GPR119 (0.42) | GPR119ERBB2CYP3A4CYP2C9KMT2A | |
| SCHEMBL357499 | 0.86 | GPR119 (0.52) | GPR119ERBB2CYP3A4CYP2C9CCNT1 | |
| SCHEMBL10171796 | 0.86 | GPR119 (0.49) | GPR119ERBB2CYP3A4CYP2C9NEK7 | |
| SCHEMBL10171761 | 0.86 | GPR119 (0.56) | GPR119ERBB2CYP3A4CYP2C9NEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | GPR119 1/4885ERBB2 451/4885CYP3A4 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.